Healthcare

This bill extends funding for respite care programs through fiscal year 2029, replacing the previous 2020-2024 authorization. It updates the definition of "family caregiver" in federal law to include "unpaid individual" instead of "unpaid adult," broadening eligibility. The legislation directly supports family caregivers and their care recipients by maintaining access to temporary relief services. It ensures existing respite care programs continue operating without interruption under the new funding period.

This bill adds Medicare coverage for home-based treatment of Alpha-1 Antitrypsin Deficiency Disorder (a rare genetic condition causing lung and liver damage). It specifically covers "augmentation therapy" (replacement protein therapy) delivered at home by qualified suppliers to Medicare Part A and B enrollees with this diagnosis who aren't in Medicare Advantage plans. The bill establishes payment for intravenous kits and up to 2 hours of nursing services per session, set at 80% of the lesser of actual cost or a defined rate. It amends Medicare rules to include this treatment under coverage, effective January 2027.

HR 3757, the Pride In Mental Health Act of 2025, provides $20 million annually (2026-2030) to fund grants for mental health services targeting LGBTQ+ youth, including nonbinary, intersex, and Two Spirit youth, and their families/caregivers. The bill mandates grantees to provide trauma-informed care, cultural competency training, school bullying prevention guidelines, and evidence-based practices while explicitly prohibiting the use of funds for conversion therapy or its promotion. It also requires the federal government to restore mental health reports on LGBTQ+ youth, conduct a national survey measuring mental health distress, and produce a report on mental health services for LGBTQ+ youth in foster care. The law directly affects these youth populations by expanding access to tailored mental health resources and data collection, with funding administered through the Substance Abuse and Mental Health Administration.

The State Strategic Stockpile Act of 2025 reauthorizes a federal program that provides funding to states for maintaining emergency medical supply stockpiles. It extends the funding period through fiscal year 2030 and adds requirements for states to coordinate with health officials and share best practices through state consortia. The bill mandates that states receiving funds must collaborate with healthcare and emergency management entities within their jurisdiction. This directly affects state health departments and emergency management agencies that administer medical stockpiles under the program.

This bill establishes eligibility for certain disability compensation and benefits for individuals who served at the Nevada Test and Training Range (NTTR). The bill establishes that onsite participation on or after January 1, 1972, and before January 1, 2005, at certain NTTR locations where there was a potential of toxic exposure is a radiation-risk activity, therefore providing a presumption of service-connection for specified conditions. The bill specifies the covered NTTR locations include a location at Indian Springs Auxiliary Airfield but do not include a location at Nellis Air Force Base or Creech Air Force Base. The bill also establishes a presumption of toxic exposure for veterans who performed active service at such NTTR locations, including airspace above such locations. Additionally, lipomas and tumor related conditions must be considered as service-connected conditions for veterans who served at the NTTR locations.

The DRIVE Act of 2025 requires the Department of Veterans Affairs (VA) to set mileage reimbursement rates for veterans at the federal government's current standard rate for employees using personal vehicles on official business, replacing the previous fixed rate of 41.5 cents per mile. It also mandates that the VA process and pay these reimbursements within 90 days of a veteran's valid request. This directly affects veterans who travel for VA medical appointments or services using their personal vehicles. The bill aligns veteran travel reimbursements with federal employee standards and ensures timely payments.

Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.

This resolution (SRES 165) is a symbolic Senate expression of disapproval, stating that the Senate considers it unacceptable for the Department of Veterans Affairs to implement a plan to fire 83,000 employees, as described in the resolution as being directed by "President Trump and Elon Musk." It calls for the VA to immediately reject and rescind this proposed reduction in force. As a non-binding resolution, it does not change policy or law but reflects the Senate’s position on the matter. The resolution directly addresses the VA’s staffing decisions but has no legal effect on employment actions.

HR 3044, the "No Vaccine Mandates in Higher Education Act," prohibits federal funding from being provided to colleges and universities that require students or staff to receive a COVID-19 vaccine for enrollment, employment, or access to services. This directly affects institutions of higher education receiving federal funds, such as those participating in student aid programs. The bill's key mechanism is withholding federal funds from any institution enforcing such vaccine mandates, as defined under the Higher Education Act of 1965. The law focuses solely on vaccine requirements, not other health or safety policies.

This bill amends the Family and Medical Leave Act (FMLA) to explicitly include "the birth of a son or daughter" as a qualifying reason for leave. It directly affects employees taking leave for childbirth, ensuring they cannot be penalized for not returning to work after such leave. The key provision requires employers to notify eligible employees that they cannot recover health insurance premiums paid during the leave if the employee does not return due to the birth. This change clarifies protections for parents using FMLA for childbirth-related leave.